Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
26 March 2020 - 8:00AM
Business Wire
Merck is Contributing 300,000 Masks to New
Jersey’s Office of Homeland Security and Preparedness to Support
COVID-19 Relief Efforts
In response to calls for personal protective equipment for
health care workers and other front-line responders battling the
COVID-19 pandemic, Merck & Co., Inc. (NYSE: MRK), known as MSD
outside the U.S. and Canada, today announced that it is donating
300,000 masks to New Jersey’s Office of Homeland Security and
Preparedness. As of Wednesday, March 25, 2020, New Jersey had
confirmed more than 3,500 novel coronavirus cases, the
second-highest in the U.S. after New York state. On Sunday, Merck
announced a donation of 500,000 masks for use in New York City.
“At Merck, we recognize that our global mission to save and
improve lives starts in New Jersey, home of our global headquarters
and thousands of our employees,” said Kenneth C. Frazier, chairman
and chief executive officer, Merck. “We extend our deepest
appreciation to the many healthcare providers and volunteers here
and around the world who are doing so much to help affected
patients and communities, and to our own employees who are focused
on delivering our critically important medicines and vaccines to
the patients who need them.”
In response to the COVID-19 pandemic, Merck remains focused on
protecting the safety of its employees and their families, assuring
that our supply of medicines and vaccines reach our patients,
contributing our scientific expertise to the development of
antiviral approaches, and supporting our healthcare providers and
the communities in which they serve.
About Merck
For more than 125 years, Merck, known as MSD outside of the
United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most
challenging diseases in pursuit of our mission to save and improve
lives. We demonstrate our commitment to patients and population
health by increasing access to health care through far-reaching
policies, programs and partnerships. Today, Merck continues to be
at the forefront of research to prevent and treat diseases that
threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire
to be the premier research-intensive biopharmaceutical company in
the world. For more information, visit www.merck.com and connect
with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200325005750/en/
Patrick Ryan (201) 452-2409
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024